Fudan Zhangjiang Bio-Pharma Schedules 29 April 2026 Board Meeting to Approve Q1 2026 Unaudited Results

Bulletin Express

04/15

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced that its board of directors will convene on Wednesday, 29 April 2026. The primary agenda item is to review and approve the unaudited consolidated financial results for the first quarter ended 31 March 2026, followed by their public release.

The board currently comprises eight members: Executive Directors Mr. Zhao Da Jun (Chairman) and Ms. Xue Yan; Non-executive Directors Mr. Shen Bo and Ms. Yu Xiao Yang; Independent Non-executive Directors Mr. Wang Hong Guang, Mr. Lam Siu Wing, and Mr. Xu Pei Long; and Employee Director Ms. Qu Ya Nan.

The announcement was released in Shanghai on 15 April 2026.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1150431751"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1150431751\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1150431751?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 18:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150431751","market":"us","top_or_hot":-1,"title":"Fudan Zhangjiang Bio-Pharma Schedules 29 April 2026 Board Meeting to Approve Q1 2026 Unaudited Results","media":"Bulletin Express","content":"<p>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced that its board of directors will convene on Wednesday, 29 April 2026. The primary agenda item is to review and approve the unaudited consolidated financial results for the first quarter ended 31 March 2026, followed by their public release.</p>\n<p>The board currently comprises eight members: Executive Directors Mr. Zhao Da Jun (Chairman) and Ms. Xue Yan; Non-executive Directors Mr. Shen Bo and Ms. Yu Xiao Yang; Independent Non-executive Directors Mr. Wang Hong Guang, Mr. Lam Siu Wing, and Mr. Xu Pei Long; and Employee Director Ms. Qu Ya Nan.</p>\n<p>The announcement was released in Shanghai on 15 April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fudan Zhangjiang Bio-Pharma Schedules 29 April 2026 Board Meeting to Approve Q1 2026 Unaudited Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFudan Zhangjiang Bio-Pharma Schedules 29 April 2026 Board Meeting to Approve Q1 2026 Unaudited Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-15 18:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced that its board of directors will convene on Wednesday, 29 April 2026. The primary agenda item is to review and approve the unaudited consolidated financial results for the first quarter ended 31 March 2026, followed by their public release.</p>\n<p>The board currently comprises eight members: Executive Directors Mr. Zhao Da Jun (Chairman) and Ms. Xue Yan; Non-executive Directors Mr. Shen Bo and Ms. Yu Xiao Yang; Independent Non-executive Directors Mr. Wang Hong Guang, Mr. Lam Siu Wing, and Mr. Xu Pei Long; and Employee Director Ms. Qu Ya Nan.</p>\n<p>The announcement was released in Shanghai on 15 April 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01349","symbol_name":"复旦张江","start_time":0,"source_url":"","article_id":"1150431751","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150431751","pubTimestamp":1776247440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced that its board of directors will convene on Wednesday, 29 April 2026. The primary agenda item is to review and approve the unaudited...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01349":"复旦张江"},"translate_title":"复旦张江生物制药定于2026年4月29日召开董事会批准2026年第一季度未经审计业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01349":1},"content_text":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. announced that its board of directors will convene on Wednesday, 29 April 2026. The primary agenda item is to review and approve the unaudited consolidated financial results for the first quarter ended 31 March 2026, followed by their public release.\nThe board currently comprises eight members: Executive Directors Mr. Zhao Da Jun (Chairman) and Ms. Xue Yan; Non-executive Directors Mr. Shen Bo and Ms. Yu Xiao Yang; Independent Non-executive Directors Mr. Wang Hong Guang, Mr. Lam Siu Wing, and Mr. Xu Pei Long; and Employee Director Ms. Qu Ya Nan.\nThe announcement was released in Shanghai on 15 April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}